Luke Miels Sells 15,579 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK) insider Luke Miels sold 15,579 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of GBX 2,160, for a total transaction of £336,506.40.

Luke Miels also recently made the following trade(s):

• On Monday, February 9th, Luke Miels sold 4,549 shares of GSK stock. The stock was sold at an average price of GBX 2,211, for a total transaction of £100,578.39.

GSK Stock Performance

Shares of LON GSK opened at GBX 2,271.34 on Thursday. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a 50 day moving average price of GBX 1,906.70 and a 200 day moving average price of GBX 1,712.78. The stock has a market capitalization of £91.64 billion, a PE ratio of 17.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK plc has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 2,282.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Analysts predict that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on GSK shares. Deutsche Bank Aktiengesellschaft lifted their target price on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research note on Thursday, January 15th. Citigroup raised their target price on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research note on Monday, February 9th. Berenberg Bank upped their price target on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research note on Monday, November 24th. UBS Group reissued a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a report on Friday, January 23rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a research report on Wednesday, January 7th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of GBX 1,917.86.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: EU clears Exdensur (twice‑yearly asthma treatment) — regulatory approval expands GSK’s respiratory franchise, supporting near‑term sales growth and strengthening the inhaled medicines revenue stream. GSK’s Exdensur gets green light from European Commission
• Positive Sentiment: AREXVY real‑world study shows reductions in RSV‑related risks (including heart attack, stroke and severe COPD/asthma exacerbations) — strengthens vaccine value proposition, which can drive uptake, payer support and longer‑term revenue for GSK’s RSV franchise. GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks
• Positive Sentiment: Five‑year collaboration with Jackson Laboratory / JAX‑NYSCF to advance human cellular models for neurodegenerative disease — strengthens translational research capabilities and could accelerate early‑stage discoveries that feed GSK’s neurodegeneration pipeline. GSK strikes 5-year deal with Jackson Laboratory
• Neutral Sentiment: Share price momentum / 1‑year high commentary — media pieces highlighting GSK’s recovery and technical strength can attract momentum traders, but do not change fundamentals. See what the epic GSK share price recovery has done
• Positive Sentiment: GSK added 420,000 shares to treasury (buyback) — modestly reduces float and can be EPS‑accretive, supporting the share price. GSK Adds 420,000 Shares to Treasury
• Negative Sentiment: Insider selling — executive Luke Miels sold 15,579 shares (~£336k) recently; routine disposals can be perceived negatively by some investors even if they’re normal personal transactions. GSK Insider Luke Miels Sells Shares

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.